Evaluation of bleed duration and adverse donor reactions during the blood donation process.

IF 1.8 4区医学 Q3 HEMATOLOGY

Vox Sanguinis Pub Date : 2025-04-14 DOI:10.1111/vox.70024

Caroline Gesu Ngunyi, Michel Noubom, Jude Eteneneng Enoh, Patrick Njukeng, Claude T Tagny, Nkenganyi Gesu, Ebaiayuknso Etambe, Nsah Bongdze-Em Lilian, Apouamoun Mouppe Amadou, Leonard Fonkeng Sama, Emmanuel Asongalem

{"title":"Evaluation of bleed duration and adverse donor reactions during the blood donation process.","authors":"Caroline Gesu Ngunyi, Michel Noubom, Jude Eteneneng Enoh, Patrick Njukeng, Claude T Tagny, Nkenganyi Gesu, Ebaiayuknso Etambe, Nsah Bongdze-Em Lilian, Apouamoun Mouppe Amadou, Leonard Fonkeng Sama, Emmanuel Asongalem","doi":"10.1111/vox.70024","DOIUrl":null,"url":null,"abstract":"Background and objectives: There are great gaps regarding the demand and supply of blood and its derivatives in the blood transfusion field, which remains a major health issue. Adverse reactions experienced in the blood donation process have been reported to be one of the demotivating factors for donors returning. This study assessed bleed duration and the occurrence of adverse donor reactions (ADRs) in a blood bank setting in Cameroon.Materials and methods: A blood bank-based experimental study was conducted over 24 months at the Bafoussam Regional Hospital, Cameroon. Signs and symptoms of ADRs were recorded from whole blood donors who bled within and above 10 min, as well as from counselled and uncounselled donors.Results: Overall, 35 of 252 (13.9%) cases presented undesirable effects from blood donation, with re-puncture-associated haematomas-occurring in 17 of 35 (5.95%)-recorded as the most common reaction. On evaluating bleed duration as a predisposing factor, 28.9% of whole blood donors with bleed duration exceeding 10 min experienced ADRs, while 10.6% of donors bled within 10 min (p = 0.0013). Whether a donor was counselled or not, it had no effect on the occurrence of ADR.Conclusion: The study identified prolonged bleeding duration as a novel predisposing factor for ADRs. Re-puncture-associated haematoma, which is an erroneous phlebotomist act, is the possible cause. The acquisition of digital vein detector devices in blood banks to curb adverse donor events, will consequently scale up blood donation and reduce the gap in the blood supply.","PeriodicalId":23631,"journal":{"name":"Vox Sanguinis","volume":" ","pages":""},"PeriodicalIF":1.8000,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vox Sanguinis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/vox.70024","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background and objectives: There are great gaps regarding the demand and supply of blood and its derivatives in the blood transfusion field, which remains a major health issue. Adverse reactions experienced in the blood donation process have been reported to be one of the demotivating factors for donors returning. This study assessed bleed duration and the occurrence of adverse donor reactions (ADRs) in a blood bank setting in Cameroon.

Materials and methods: A blood bank-based experimental study was conducted over 24 months at the Bafoussam Regional Hospital, Cameroon. Signs and symptoms of ADRs were recorded from whole blood donors who bled within and above 10 min, as well as from counselled and uncounselled donors.

Results: Overall, 35 of 252 (13.9%) cases presented undesirable effects from blood donation, with re-puncture-associated haematomas-occurring in 17 of 35 (5.95%)-recorded as the most common reaction. On evaluating bleed duration as a predisposing factor, 28.9% of whole blood donors with bleed duration exceeding 10 min experienced ADRs, while 10.6% of donors bled within 10 min (p = 0.0013). Whether a donor was counselled or not, it had no effect on the occurrence of ADR.

Conclusion: The study identified prolonged bleeding duration as a novel predisposing factor for ADRs. Re-puncture-associated haematoma, which is an erroneous phlebotomist act, is the possible cause. The acquisition of digital vein detector devices in blood banks to curb adverse donor events, will consequently scale up blood donation and reduce the gap in the blood supply.

查看原文本刊更多论文

献血过程中出血持续时间及献血者不良反应的评价。

背景和目标：在输血领域，血液及其衍生物的需求和供应存在巨大差距，这仍然是一个主要的卫生问题。据报道，献血过程中出现的不良反应是导致献血者再次献血的原因之一。本研究评估了喀麦隆血库出血持续时间和献血者不良反应（adr）的发生情况。材料和方法：在喀麦隆巴富萨姆地区医院进行了为期24个月的血库实验研究。记录在10分钟及以上出血的全血献血者以及接受咨询和未接受咨询的献血者的不良反应体征和症状。结果：总的来说，252例中有35例（13.9%）出现了献血后的不良反应，35例中有17例（5.95%）出现了再穿刺相关血肿，这是最常见的反应。在评估出血持续时间作为诱发因素时，28.9%出血持续时间超过10 min的全血献血者发生adr， 10.6%出血时间在10 min以内（p = 0.0013）。献血者是否被告知，对不良反应的发生没有影响。结论：研究发现出血时间延长是adr的一个新的易感因素。再穿刺相关血肿，这是一个错误的抽血，是可能的原因。在血库中使用数字静脉检测设备以遏制不良献血者事件，从而扩大献血规模并减少血液供应缺口。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Vox Sanguinis 医学-血液学

CiteScore

4.40

自引率

11.10%

发文量

156

审稿时长

6-12 weeks

期刊介绍： Vox Sanguinis reports on important, novel developments in transfusion medicine. Original papers, reviews and international fora are published on all aspects of blood transfusion and tissue transplantation, comprising five main sections: 1) Transfusion - Transmitted Disease and its Prevention: Identification and epidemiology of infectious agents transmissible by blood; Bacterial contamination of blood components; Donor recruitment and selection methods; Pathogen inactivation. 2) Blood Component Collection and Production: Blood collection methods and devices (including apheresis); Plasma fractionation techniques and plasma derivatives; Preparation of labile blood components; Inventory management; Hematopoietic progenitor cell collection and storage; Collection and storage of tissues; Quality management and good manufacturing practice; Automation and information technology. 3) Transfusion Medicine and New Therapies: Transfusion thresholds and audits; Haemovigilance; Clinical trials regarding appropriate haemotherapy; Non-infectious adverse affects of transfusion; Therapeutic apheresis; Support of transplant patients; Gene therapy and immunotherapy. 4) Immunohaematology and Immunogenetics: Autoimmunity in haematology; Alloimmunity of blood; Pre-transfusion testing; Immunodiagnostics; Immunobiology; Complement in immunohaematology; Blood typing reagents; Genetic markers of blood cells and serum proteins: polymorphisms and function; Genetic markers and disease; Parentage testing and forensic immunohaematology. 5) Cellular Therapy: Cell-based therapies; Stem cell sources; Stem cell processing and storage; Stem cell products; Stem cell plasticity; Regenerative medicine with cells; Cellular immunotherapy; Molecular therapy; Gene therapy.